Acucela Founder to Speak at Ophthalmology Conference.Dr. Kubota Among Featured Speakers at Angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. , Exudation exudation /ex·u·da·tion/ (eks?u-da´shun) 1. the escape of fluid, cells, and cellular debris from blood vessels and their deposition in or on the tissues, usually as the result of inflammation. 2. an exudate. and Degeneration Symposium BOTHELL, Wash. -- Acucela founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Ryo Kubota will be a featured speaker at a symposium highlighting revolutionary pharmacotherapies in development and clinical practice to treat debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction eye diseases, the company announced today. Dr. Kubota has been invited to speak about clinical research associated with Acucela's development of ACU-4429, an oral treatment for a condition known as age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ) that causes blindness in 30 million people worldwide. Acucela's research focuses on halting the progress of dry AMD, the leading cause of blindness in people over 50. "Acucela is developing an innovative oral therapy to cure diseases that most commonly cause age-related blindness," Dr. Kubota said. "We believe this treatment will potentially prevent tens of millions of people globally from losing their eyesight. We are excited for the opportunity to showcase our work to colleagues." Acucela, based in Bothell, Wash., is developing ACU-4429 in partnership with Otsuka Pharmaceutical, Co., Ltd., a large Japanese company. The drug is in Phase I clinical trials. Dr. Kubota will make his presentation at Angiogenesis, Exudation and Degeneration 2009, hosted by the University of Miami's Bascom Palmer Eye Institute, at 11:20 a.m. on Feb. 21 at the Ritz-Carlton Hotel in Key Biscayne, Fla. The one-day symposium attracts retinal specialists, general ophthalmologists and basic scientists from all over the country. Speakers will focus on understanding and treating neovascular and exudative exudative of or pertaining to a process of exudation. exudative diathesis a disease of young pigs and chickens caused by a nutritional deficiency of vitamin E. Characterized by severe edema of the subcutaneous tissues. diseases, specifically those that manage dry AMD, neovascular AMD, macular edema, diabetic retinopathy and retinopathy of prematurity retinopathy of prematurity n. Abnormal replacement of the sensory retina by fibrous tissue and blood vessels, occurring mainly in premature infants who are placed in a high-oxygen environment. . Presentations will review the latest in clinical research investigating imaging techniques and emerging therapies for blinding retinal diseases. About Acucela Acucela Inc. is a clinical-stage biotechnology company focused on developing new drug therapies for blinding eye diseases such as age-related macular degeneration (AMD), Stargardt disease, diabetic retinopathy and retinopathy of prematurity, as well as dry eye. Founded in 2002, Acucela works with proprietary disease-specific assays and technologies to identify and develop compounds that may safely and effectively treat retinal diseases. For more information, please visit www.acucela.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion